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Abstract
Background: The leishmaniasis is a group of diseases with a broad range of clinical
manifestations caused by several species of parasites belonging to the genus
Leishmania. LL-37/hCAP18, the only cathelicidin in human, is expressed as an 18-
kDa preproprotein. The most prominent function of cathelicidin is their ability to inhibit
propagation of a diverse range of microorganisms, which occurs at a micromolar range.
Objective: The study was aimed to evaluate the LL37 plasma level in Leishmania
Sudanese patients.
Methods: In a case-control study, 300 subjects were enrolled (200 as case and
100 controls); 5 ml venous blood was collected in EDTA container, then plasma was
obtained and stored frozen at –80°C. LL 37 was estimated using competitive ELISA.
The data were analyzed using SPSS version 21.
Results: The results revealed that 115 (57%) of Leishimania patients were male and
85 (43%) were female. Plasma LL 37 level was significantly increased in Leishmania
patients (1.30 ± 0.71) compared to the control (0.21 ± 0.20) with (p-value 0.000).
Conclusion: Leishmania patients had higher levels of plasma LL37, suggesting effective
antimicrobial immunity process enhancing healing of cutaneous leishmaniasis.
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1. Introduction
The leishmaniases are a group of diseases with a broad range of clinical manifestations
caused by several species of parasites belonging to the genus Leishmania (Family:
Trypanosomatidae). The Leishmania parasite, a haemo-flagellate protozoan organism,
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is exclusively transmitted by the bite of a female sandfly of the genera Phlebotomus
or Lutzomyia. There are three clinical forms of leishmaniasis: visceral leishmaniasis
(VL) including post-kala-azar dermal leishmaniasis (PKDL), cutaneous leishmaniasis (CL),
and CL with the involvement of the mucous membranes, also called mucocutaneous
leishmaniasis (MCL) [1]. CL in Sudan is similar to the disease in other endemic areas.
There are three types: nodular or nodular-ulcerative, ulcerative, and diffuse infiltrative [2].
Most patients havemultiple lesions of themodular or ulcerative type[3]. Typically, lesions
start to heal spontaneously after approximately three months [4]. Unlike American
mucocutaneous leishmaniasis, Sudanese mucosal leishmaniasis (SML) is not preceded
or accompanied by cutaneous lesions. Three clinical presentations of SML have been
reported: nasal, which is characterized by nasal obstruction, mucoid discharge, and
slight bleeding; oral, where the patient complains of a sensation of fullness of the
mouth, spontaneous loss of teeth and bleeding from the gum; and oro-nasal, where the
hard palate may perforate. The disease is almost exclusively found in adult males (20–
70 yr) [5]. Cathelicidins are a family of evolutionarily conserved antimicrobial peptides
described in mammals, birds, fish, and reptiles. This class of pleiotropic peptides is
an important mediator of innate immunity against microbial pathogens and provides
first-line defense against infection by promoting rapid elimination of pathogens. LL-
37/hCAP18 is the only cathelicidin in human [6]. The most prominent function of catheli-
cidins is their ability to inhibit propagation of a diverse range of microorganisms, which
occurs at micromolar range [7]. Besides their direct antimicrobial action, recent studies
have revealed multiple functions of cathelicidins in many other activities relating to
tissue repair and innate immunity. The human and porcine cathelicidins, LL-37/hCAP18
and PR-39, respectively, for examples, have been reported to modulate the activity of
immune and 7, 8, 9 inflammatory cells [8, 9]. Cathelicidins have also been shown to
promote re-epithelialization of human skin wounds [10] and rat gastric ulcer [11]. The
study was aimed to evaluate the LL37 plasma level in Leishmania Sudanese patients.
2. Methods
In this case-control study, 300 subjects were enrolled, 200 diagnosed with CL infection
and 100 as control (free of CL infection). Blood samples were drawn after obtaining
written informed consent from the patients; 5 ml of venous blood was collected from
each subject in EDTA container, then plasma was obtained and stored frozen at –80°C.
LL 37 was estimated using competitive ELISA. Data were expressed as percentage and
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differences in variables mean levels between the two groups were tested by Student’s
𝑡-test.
3. Results and Discussion
Figure 1: Distribution of patients according to the gender.
Figure 2: Distribution of patients according to age.
The results showed that 115 (57.0%) of leishmania patients were males and 85
(43.0%) were females (Figure 1). Regarding the age group, the higher proportion (47%) of
leishmania patients was found among the 12–29 yr old, followed by 30–47 yr, and then
48–65 yr (Figure 2). The mean values of LL-37 (plasma level ng/ml) for the cases was
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Figure 4: Mean of LL-37 across gender.
1.30 ± 0.71 and for the control group was 0.21 ± 0.25, significant differences increase
was found between cases and control groups with a p-value of 0.000. (Figure 3). The
mean LL-37 level was significantly increased in female leishmania patients compared
to male leishmania patients p-value 0.000 (Figure 4). LL-37 is one of the most studied
antimicrobial peptides that play important roles in the innate immune system. In addition
to its anti-infective activities, LL-37 stimulates local angiogenesis, acts synergistically
with the epidermal growth factor receptor to promote epithelial growth, and attracts
monocytes and neutrophils through formyl peptide receptors on these cells. In this
way, the peptide helps orchestrate the inflammatory process [12–14]. Unlike the present
study, which studied the plasma level of LL-37, Kulkarni MM et al. studied the role of
this host peptide in control of the dissemination of cutaneous infection by the parasitic
protozoan Leishmania, using amouse knock-out model in cathelicidin-type antimicrobial
peptides (CAMP) [15]. They found that the presence of pronounced host inflammatory
infiltration in lesions and lymph nodes of infected animals was CAMP-dependent. To
our knowledge, this is the first study of plasma LL37 in cutaneous leishmania patients.
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The present study data revealed an increase in plasma LL 37 levels among cutaneous
leishmania patients suggesting increased expression of LL 37 is moreover able to limit
dissemination of CL. These results support the Kulkarni MM et al.’s suggestion that
CAMP is crucial for the local control of cutaneous lesion development and parasite
growth and metastasis [15].
4. Conclusion
Leishmania patients have higher levels of plasma LL37, suggesting effective antimicro-
bial immunity process enhancing healing of CL.
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